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Summary 6 
Objectives : Although infectious disease (ID) consultation has been associated with lower 7 
mortality in Staphylococcus aureus bloodstream infections, it is still not mandatory in many 8 
centers. This study aimed at assessing the impact of ID consultation on diagnostic and 9 
therapeutic management of methicillin-resistant S. aureus (MRSA) bacteremia. 10 
Methods : Retrospective cohort study of all patients with MRSA bacteremia from 2001 to 11 
2010. ID consultations were obtained on request between 2001 and 2006 and became 12 
mandatory since 2007. 13 
Results : 156 episodes of MRSA bacteremia were included, mostly from central venous 14 
catheter (32%) and skin and soft tissue (19%) infections. ID consultation coverage was 58% 15 
between 2001 and 2006 and 91% between 2007 and 2010. ID consultation was associated 16 
with more echocardiography (59% vs. 26%, p<0.01), vancomycin trough level measurements 17 
(99% vs. 77%, p<0.01), follow-up blood cultures (71% vs. 50%, p=0.05), deep-seated 18 
infections (43% vs. 16%, p<0.01), more frequent infection source control (83% vs. 57%, 19 
p=0.03), a longer duration of MRSA-active therapy (median and IQR: 17 days, 13-30, vs. 12, 20 
3-14, p<0.01) and a 20% reduction in 7-day, 30-day and in-hospital mortality. 21 
Conclusions : ID consultation was associated with a better management of patients with 22 
MRSA bacteremia and a reduced mortality. 23 
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Introduction 26 
Staphylococcus aureus is a leading cause of both community-acquired and healthcare-27 
associated bloodstream infections, with a reported mortality of 20-40% that has remained 28 
stable over the last decades [1-4]. Factors associated with mortality include comorbidities, 29 
severity of infection, community acquisition, inappropriate treatment, failure to identify a 30 
primary source of infection and to remove intravascular foci of infection [1, 2, 5-8]. Several 31 
studies have shown a higher mortality rate associated with methicillin-resistant S. aureus 32 
(MRSA) infection compared to methicillin-susceptible S. aureus (MSSA), although this issue 33 
remains controversial and could be related to confounding factors such as age, underlying 34 
conditions and inappropriate treatment rather than methicillin-resistance per se [3, 7-9]. 35 
Timely and effective management of S. aureus bloodstream infections is of upmost 36 
importance. Several publications have reported a significant impact of infectious diseases 37 
(ID) consultation in improving diagnostic work-up and outcome of S. aureus bacteremia [1, 38 
10-12]. Although some centers have reported an impact of mandatory consultation, , it is still 39 
not applied universally, with proportions of S. aureus bacteremia seen by ID specialists as 40 
low as 27-51% [5, 11-13]. Besides lack of randomized clinical trials, one potential obstacle to 41 
universal uptake is limited knowledge of which patients would particularly benefit from ID 42 
consultation. Specifically, published data on impact of ID consultation on MRSA bacteremia 43 
are scarce [14].  44 
The aim of the present study was to assess the impact of ID consultation on the diagnostic 45 
workup, choice of antimicrobial treatment, source control and patient’s outcome of methicillin-46 
resistant S. aureus (MRSA) bacteremia. 47 
  48 
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Methods 49 
Study setting. Our hospital is a 1000-bed tertiary-care center with 36000 admissions per 50 
year. The proportion of MRSA among clinical S. aureus isolates was 12% between 2001 and 51 
2008, and increased to 23% in 2010. The microbiology laboratory reports daily all positive 52 
blood cultures to the physician in charge and to ID physicians. 53 
Study design. To assess the impact of ID consultation on the diagnostic workup, choice of 54 
antimicrobial treatment, source control and patient’s outcome of MRSA bacteremia, we 55 
conducted a retrospective cohort study. All MRSA bacteremia that occurred in adult patients 56 
between January 2001 and December 2010 were identified through the microbiology 57 
laboratory database. Medical charts and written ID consultations were reviewed for 58 
demographic and clinical data including sex, age, underlying conditions, site of infection, 59 
antimicrobial therapy, source control and clinical outcome. Exclusion criteria were: age under 60 
18, transfer to another hospital or initiation of palliative care for end-of-life situations within 61 
72h of bacteremia onset or death before result of blood cultures. The study was approved by 62 
the institutional ethics committee; informed consent was not needed. 63 
Definitions. MRSA bacteremia was defined as the occurrence of at least one positive blood 64 
culture for MRSA in the presence of concomitant signs of infection. Recurrence of MRSA 65 
bacteremia within the same patient was considered a distinct episode only if occurring more 66 
than 12 weeks after the initial episode and once antimicrobial therapy was completed [11]. 67 
MRSA bloodstream infections were classified as healthcare-associated or community-68 
associated infections according to CDC criteria (http://www.cdc.gov). Healthcare-associated 69 
bacteremia was further subclassified as hospital-onset or community-onset infection if it 70 
occurred more than 48h after admission or less than 48h after admission, respectively. 71 
Except for skin and soft tissue, only microbiologically-documented primary sites of infection 72 
mentioned in the medical charts were considered. Deep-seated infections were defined as 73 
microbiologically or radiologically documented remote foci. Catheter-related bloodstream 74 
infection was defined as exit site infection and/or a catheter tip culture growing > 15 MRSA 75 
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cfu with concomitant bacteremia [15]. Modified Duke criteria were used to define infective 76 
endocarditis [16]. Severe infection was defined as bacteremia with severe sepsis or septic 77 
shock [17]. Antimicrobial treatment was considered empirical before the identification of 78 
MRSA in blood cultures and targeted thereafter. Antimicrobial therapy was considered 79 
appropriate when a parenteral anti-infectious agent with in vitro activity against MRSA was 80 
used. Appropriate duration of treatment was 14 days for uncomplicated bacteremia and at 81 
least 28 days for complicated bacteremia, using standard definitions [18]. 82 
Impact of ID consultation. Between 2001 and 2006, ID consultations were obtained on 83 
request. After 2006, a senior ID resident supervised young ID consultants and checked that a 84 
formal ID consultation was performed on a mandatory basis within the same day for all 85 
patients in whom blood cultures were positive for suspected or confirmed S. aureus. Follow-86 
up consultations were performed systematically as long as infection was ongoing or until 87 
discharge. All initial and follow-up consultations resulted in written reports transmitted to 88 
physicians in charge the same day of the evaluation. ID advice for MRSA bacteremia 89 
included follow-up blood cultures after 48h of appropriate treatment and then until 90 
sterilization, transthoracic and/or transoesophagal echocardiography for suspected 91 
endocarditis or sustained bacteremia, use of vancomycin as first-line antimicrobial agent at 92 
an initial dose 15 mg/kg of body weight with adjustment to through level targeting 15 mg/l, 93 
source control by eradication of infectious foci, such as removal of peripheral or central 94 
venous catheters (CVC), and whenever possible drainage of deep-seated sites. The 95 
following variables were compared between episodes managed with and without ID 96 
consultations: early (7-day), late (30-day) and in-hospital mortality; performance of follow-up 97 
blood cultures, echocardiography when indicated and diagnosis of deep-seated sites of 98 
infection; appropriateness of empirical and definitive treatment including duration of 99 
antimicrobial therapy and vancomycin trough level measurement; eradication of removable 100 
foci including removal of all catheters and surgical debridement/drainage. 101 
Statistical analysis. Categorical variables were compared using Fisher’s exact test. 102 
Continuous variables were compared using parametric Student’s t test when normally 103 
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distributed and non-parametric Mann-Whitney U test otherwise. Potential predictors of 7-day 104 
and 30-day mortality were first assessed in univariate analysis and then included into a 105 
logistic regression analysis whenever their p-value was ≤0.2. Kaplan-Meier (KM) and Cox 106 
survival analysis were performed to assess the impact of ID consultation on in-hospital 107 
mortality and comparison between groups was performed by the log-rank test for KM and 108 
Wald test for Cox. Two-sided statistical significance was set at p=0.05. Cox proportional 109 
hazards assumption was assessed by inspection of the log(-log(survival)) versus log of 110 
survival time graph for each regressor, as well as by formal diagnostic testing. Results of 111 
logistic regression analyses are presented as Odds Ratios (OR) and those of Cox analyses 112 
as Hazard Ratios (HR). Data were analyzed using Stata 12.1 (Stata Corporation, College 113 
Station, Texas, USA) and GraphPad Prism 5.0 (GraphPad Software, San Diego, California, 114 
USA). 115 
Results 116 
Study population. Of 176 identified episodes of MRSA bacteremia, 20 were excluded for 117 
the following reasons: age < 18 (n=2), transfer to another hospital (n=3), initiation of palliative 118 
care (n=3) within 72h of bacteremia, or death before result of blood cultures (n=12). Thus, 119 
156 episodes that occurred in 148 patients (six patients had two episodes and one patient 120 
had three) were analyzed. Only thirty (20%) patients did not receive ID consultation. 121 
Demographic and clinical characteristics of the 148 patients with or without ID consultation 122 
are shown in Table 1. The only significant differences between groups were older age and a 123 
higher proportion of nursing home residents in patients without ID consultation. All but three 124 
patients had at least one underlying condition associated with an increased risk for MRSA 125 
carriage and 57% had previously-documented MRSA colonization. 126 
MRSA bacteremia. Annual incidence of MRSA bacteremia is shown in Figure 1. Our 127 
institution faced a large nosocomial MRSA outbreak in 2009-2010 and the incidence rate of 128 
MRSA bloodstream infections increased to 0.9 per 1000 admissions in 2010. One hundred 129 
fifty-one episodes (97%) were healthcare-associated infections (116 hospital-onset and 35 130 
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community-onset) and only five (3%) community-associated infections. Primary sites of 131 
infection were: CVC (50), skin (30), urinary tract (21), respiratory tract (21), surgical site (12), 132 
peripheral catheter (9) and abdomen (3). In 36 episodes (23%), no primary focus of infection 133 
was detected. Deep-seated sites of infection were diagnosed in 58 episodes (38%). 134 
Characteristics of MRSA bacteremia episodes with or without ID consultation are 135 
summarized in Table 2. 136 
ID consultations. An ID consultation was performed in 124 episodes (80%). The proportion 137 
of MRSA bacteremia episodes managed with ID consultation rose from a median of 58% in 138 
2001-2006 to 91% in 2007-2010 (p<0.01) (Figure 1). Between 2007 and 2010, seven 139 
patients were not seen by ID specialists despite mandatory ID consultation. Although the 140 
reason for not having a consultation was not known precisely, the only factor associated with 141 
not having a consultation was older age (median age 81 vs. 71 years, p=0.04). Median time 142 
from blood culture sampling to initial consultation was 1 day (IQR 0-2). Median ID follow-up 143 
was 13 days (IQR: 6-27).  144 
Diagnostic work-up and identification of primary and deep-seated site of infection 145 
(Table 2). Catheters and skin and soft tissue were identified as the most frequent primary 146 
foci. In the ID group, significantly more echocardiography (59% vs. 26%, p<0.01) and more 147 
follow-up blood cultures (71% vs. 50%, p=0.05) were performed. Deep-seated sites of 148 
infection were diagnosed 4 times more often in the ID consultation group than in the 149 
comparative group (39% vs. 12%, p<0.01). All episodes with endocarditis, deep-seated 150 
osteoarticular sites (except one sternitis) or deep systemic emboli were managed with an ID 151 
consultation. Nine out of 13 cases of endocarditis had definite endocarditis with vegetations 152 
seen on echocardiography. One patient not seen by ID consultation was discharged after 2 153 
weeks of therapy for primary bacteremia without surveillance blood cultures or 154 
echocardiography and was re-admitted 3 weeks later with a diagnosis of mitral valve 155 
endocarditis. 156 
Management of MRSA bacteremia (Table 3). Patients in the ID group were hospitalized for 157 
a significantly longer period overall and after bacteremia onset. Empirical antibiotic therapy 158 
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was given in 68% of patients with ID consultation vs. 65% in controls (p=0.53). One third of 159 
patients received no antimicrobial treatment before positive blood culture results. Empirical 160 
therapy was appropriate in 49% vs. 30% respectively, although the difference did not reach 161 
statistical significance (p=0.14). Targeted treatment was appropriate in all episodes of both 162 
groups. Vancomycin was used as first-line targeted therapy in 115 (94%) episodes managed 163 
with ID consultation vs. 32 (100%) in controls, daptomycin in 6 (5%) vs. 0, linezolid in 2 (2%) 164 
vs. 0 and teicoplanin in 1 (1%) vs. 0. Reasons for not using vancomycin were allergy to 165 
glycopeptides (4), intent to obtain a more bactericidal effect (3), linezolid use for MRSA 166 
pneumonia (1) and impossibility to obtain a venous access (1). Duration of antimicrobial 167 
therapy was significantly longer in ID consultation group. A higher proportion of patients were 168 
treated for more than 14 or 28 days in ID group (71% vs. 39%, p<0.01, 31% vs. 10%, 169 
p=0.02, respectively). Among 78 evaluable episodes of uncomplicated bacteremia, 170 
appropriate duration of treatment (≥ 14 days) was 51/59 (86%) in the ID consultation group 171 
vs. 11/19 (58%, p=0.02) in controls. Among 37 evaluable episodes of complicated 172 
bacteremia, appropriate duration of treatment (≥ 28 days) was 31/36 (86%) vs. 0/1 (0%), 173 
respectively. Vancomycin trough level was measured in 99% of patients receiving this drug 174 
for ≥48h in episodes managed with ID consultation vs. 77% in others (p<0.01). No significant 175 
difference was observed in trough levels between the two groups. Eradication of removable 176 
infectious foci was performed significantly more often in the ID consultation group (83% vs. 177 
57%, p=0.03). However, interventions were not statistically different when compared 178 
individually. 179 
Patient’s Outcome (Table 3). Seven-day, 30-day and in-hospital mortality for all episodes 180 
were 8%, 24% and 34%, respectively. ID consultation was associated with a marked 181 
decrease in 7-day (5% vs. 22%, OR 0.18, 95% CI 0.06-0.59, p<0.01), 30-day (20% vs. 40%, 182 
OR 0.38, 95% CI 0.16-0.90, p=0.03) and in-hospital mortality (29% vs. 53%, HR 0.38, 95% 183 
CI 0.20-0.74, p<0.01) (Table 3). The cumulative probability of death at 30 days was 184 
significantly higher in the non-ID group (p<0.01 by the log-rank test) (Figure 2). No time 185 
period effect was found after investigating the interaction between ID consultation and the 186 
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indicator variables for the MRSA outbreak period and for the mandatory ID consultation 187 
period. Likewise, Cox’s proportional assumption was not rejected by the variable ID 188 
consultation. In univariate analysis, factors significantly associated with higher early (7-day) 189 
and late (30-day) mortality were pneumonia, severe infection, absence of ID consultation and 190 
lack of source control (Figure 3). Inappropriate empirical antimicrobial therapy and lack of 191 
CVC removal were not associated with an increase in early or late mortality. Vancomycin 192 
trough level tended to be lower in patients who died within the first 7 days (median 9.3 mg/l, 193 
IQR 8.3-15.8 vs. 13.6, 10.6-16.1, p=0.24), although the difference was not significant. In 194 
multivariate analysis, predictors of early and late mortality were: severity of infection (OR 195 
32.56, 95% CI 4.31-246.11, p<0.01 and OR 4.31, 95% CI 1.68-11.07, p<0.01, respectively), 196 
pneumonia (OR 5.26, 95% CI 1.39-19.81, p=0.01 and OR 3.02, 95% CI 1.40-6.51, p<0.01), 197 
absence of ID consultation (OR 30.19, 95% CI 3.76-242.18, p<0.01 and OR 3.74, 95% CI 198 
1.34-10.43, p=0.01) and lack of source control (OR 10.03, 95% CI 1.39-19.81, p=0.01 and 199 
OR 3.69, 95% CI 1.22-11.13, p=0.02). 200 
Discussion 201 
In the present study, we found a major impact of ID consultation on management and 202 
outcome of MRSA bacteremia in hospitalized patients with a relative reduction of 30-day 203 
mortality from 40% to 20%, an effect that remained significant after adjustment for 204 
confounding factors in logistic regression analysis. ID consultation was also associated with 205 
more frequent identification of CVC infection and deep-seated sites of infection, as well as 206 
more frequent eradication of removable infectious foci. 207 
In 1998, Fowler et al. showed that compliance to standard-of-care management of S. aureus 208 
bacteremia provided by ID specialist could improve diagnosis of metastatic complication, 209 
clinical cure and reduce relapses [10]. Since then, the usefulness of ID consultation in this 210 
setting has been confirmed by several studies, although early reports failed to demonstrate 211 
an impact on survival [1, 11, 19]. The last five years, some retrospective data have 212 
suggested that ID consultation could also have an impact on mortality, especially within the 213 
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first 28 days of bacteremia [5, 9, 12-14, 20]. However, some of these studies included 214 
patients dying before blood culture results or untreated because of palliative context, raising 215 
concerns about the existence of a survival bias favoring patients living long enough to be 216 
seen by ID specialists [9, 13, 14, 20]. These reports combined healthcare-associated and 217 
community-acquired S. aureus bacteremia, with various rates of methicillin-resistance 218 
(mainly MSSA), as well as various rates of ID consultation coverage (27-82%) depending on 219 
ID consultation policy (on request vs. mandatory), making comparisons difficult. The present 220 
study confirmed the major impact of mandatory ID consultation on mortality in patients with 221 
healthcare-associated MRSA bacteremia after exclusion of palliative patients and death 222 
before result of blood cultures. 223 
The likelihood of appropriate empirical therapy was quite low in patients who did and did not 224 
receive ID consultation. This observation resulted probably from the fact that empirical 225 
MRSA-active therapy upon growth of Gram-positive cocci in blood cultures was not standard 226 
of care in our institution due to the low prevalence of MRSA between 2001 and 2008 (12%). 227 
Robinson et al. found that receiving an effective empirical therapy was the only variable 228 
associated with reduced mortality by multivariate analysis in patients managed with ID 229 
consultation [12]. Indeed, several studies have reported that inadequate empirical treatment 230 
or delayed therapy were strong predictors of fatal outcome and contributed to the higher 231 
mortality observed with MRSA compared to MSSA [8, 21, 22]. In this study, we found that ID 232 
consultation was associated with more frequent administration of appropriate empirical 233 
therapy but this variable was surprisingly not a predictor of survival at 7 or 30 days, not even 234 
in univariate analysis. In addition to the small sample size limiting the power to detect such a 235 
difference, this finding is also probably due to the very short time between blood culture 236 
sampling and start of appropriate definitive treatment (median 1 day, IQR 0-2), 73% of 237 
patients receiving appropriate therapy within 24 hours and 95% within 48 hours. Accordingly, 238 
Lodise et al. found that the time breakpoint after obtaining positive blood culture beyond 239 
which delayed appropriate treatment increased S. aureus bacteremia mortality was 45 hours 240 
[22]. Delayed treatment beyond was independently associated with a 1.7-fold increase in 241 
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mortality. Taken together with the present data, these findings might suggest that 242 
hemodynamically stable patients could tolerate the absence of appropriate treatment during 243 
the first 24 (to 45) hours, although our study was not adequately powered to address this 244 
question. However, an MRSA-active empirical therapy should be initiated as soon as 245 
possible in all situations. 246 
In patients with MRSA bacteremia, ID consultations are associated with lower mortality 247 
probably thanks to a bundle of diagnostic and therapeutic measures that allow better clinical 248 
management and improve the outcome. A crucial aspect in management of S. aureus 249 
bacteremia is source control and some of the previous studies have reported that source 250 
control is more often associated with ID consultation [11, 13]. Our data confirm these findings 251 
and show that lack of source control is independently associated with increased mortality. In 252 
episodes managed without ID specialists, the most frequently reported primary source of 253 
infection was the urinary tract, an uncommon origin for S. aureus infection. It is possible that 254 
MRSA bacteriuria was misinterpreted as the primary source of infection while in fact it more 255 
probably reflected hematogenous renal seeding, a current finding in S. aureus bacteremia 256 
[23]. Conversely, CVC infection was the most frequent primary source and deep-seated sites 257 
were diagnosed more often in the ID consultation group. Accordingly, source control was 258 
achieved significantly more often in the latter group, although the difference was not 259 
statistically significant when comparing removal of CVC and surgical debridement 260 
individually, likely due to the small sample size. Although none of these factors influenced 261 
mortality in univariate analysis, source control was associated with reduced mortality in 262 
multivariate analysis for 7-day, 30-day and in-hospital mortality. Therefore, reduced mortality 263 
associated with ID consultation could have been related to a bundle of actions, such as early 264 
initiation of appropriate therapy, removal of infected CVC and surgical debridement. 265 
The present study has several limitations. The low percentage of patients without ID 266 
consultation limited the power to detect differences in patients who did and did not receive ID 267 
consultation. The retrospective design of the study is another limitation. Yet, it seems unlikely 268 
that a prospective, randomized trial addressing the impact of ID consultation on mortality will 269 
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ever be conducted for ethical reasons given the increasing amount of data suggesting a 270 
better outcome in S. aureus bacteremia managed by ID specialists. However, data collection 271 
bias was limited by the fact that clinical and microbiological information was available for all 272 
patients and prospectively written ID consultations allowed an accurate assessment of 273 
infection management. Attributable mortality being difficult to assess retrospectively, crude 274 
mortality was chosen as the primary endpoint of the study, as in previous studies [1, 5, 12, 275 
20]. Overrepresentation of terminally-ill patients in episodes treated without ID specialists is a 276 
classical bias in retrospective analyses, but this limitation was minimized in the present study 277 
by excluding palliative patients. Moreover, patients seen by ID specialists tended to have a 278 
more severe infection at the time of diagnosis and were hospitalized for a longer period after 279 
diagnosis, making it unlikely that difference in mortality was simply due to imbalance in 280 
severity of infection. Finally, as the majority of bloodstream infections were healthcare-281 
associated, these results might not be generalized to community-acquired MRSA infections. 282 
In conclusion, the present results indicate that early intervention of ID specialists is 283 
associated with a better management and lower mortality among patients with MRSA 284 
bacteremia. ID consultation was associated with more frequent identification of CVC 285 
infections and deep-seated foci, better antibiotic management with more frequent use of 286 
MRSA-active empirical treatment and longer duration of therapy, and more frequent infection 287 
source control. ID consultation should be mandatory for all cases of MRSA bacteremia.  288 
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Table 1. Characteristics of patients with MRSA bacteremia with or without infectious 384 
diseases (ID) consultation. 385 
Characteristics 
All 
n=148
*
 
ID consultation 
n=118 
No ID 
consultation 
n=30 
p-value 
Male sex 107 (72) 85 (72) 22 (73) NS 
Age, median years (IQR) 71 (59-78) 71 (59-77) 77 (59-83) 0.04 
Known MRSA colonization 84 (57) 70 (59) 14 (47) NS 
Hospital stay within previous 12 months 100 (68) 80 (68) 20 (67) NS 
Underlying conditions     
Hemodialysis 10 (7) 9 (8) 1 (3) NS 
Diabetes 44 (30) 38 (32) 6 (20) NS 
Malignancy 31 (21) 25 (21) 6 (20) NS 
Peripheral arteriopathy 23 (15) 19 (16) 4 (13) NS 
Joint prosthesis 10 (7) 10 (8) 0 (0) NS 
Prosthetic valve 9 (6) 8 (7) 1 (3) NS 
Pacemaker 3 (2) 3 (2) 0 (0) NS 
Immunosuppression 19
**
 (13) 16 (13) 3 (10) NS 
Nursing home resident 14 (9) 7 (6) 7 (27) <0.01 
Injection drug use 5 (3) 4 (3) 1 (3) NS 
Data are number of patients (%) unless indicated otherwise. IQR: interquartile range. NS: not significant. 386 
*
 six patients had 2 MRSA bacteremic episodes and one had 3: only the initial episode was considered.  387 
**
 HIV infection (6), solid organ transplant recipients (8), immunosuppressive therapy (4), neutropenia (3). 388 
  389 
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Table 2. Characteristics of MRSA bacteremia episodes with or without infectious 390 
disease (ID) consultation. 391 
Characteristics 
ID consultation 
n=124 
No ID consultation 
n=32 
p-value 
Acquisition of infection    
Healthcare-associated, hospital-onset 93 (75) 23 (72) NS 
Hospital stay from admission to 
bacteremia, median days (IQR) 
16 (1-36) 9 (1-24) NS 
Healthcare-associated, community-onset 26 (21) 9 (28) NS 
Community-associated 5 (4) 0 NS 
ICU stay at time of bacteremia 22 (18) 3 (9) NS 
ICU admission within 72h of bacteremia 20 (16) 2 (6) NS 
Severe sepsis / septic shock 32 (26) 5 (16) NS 
Primary source of infection (≥ 1 possible)    
Unknown 28 (23) 8 (25) NS 
Catheters 50 (40) 9 (28) NS 
peripheral 6 (5) 3 (9) NS 
central 44 (35) 6 (19) 0.09 
Skin and soft tissue 22 (18) 7 (22) NS 
Lung 19 (15) 2 (6) NS 
Urinary tract 14 (11) 7 (22) NS 
Abdomen 2 (2) 1 (3) NS 
Surgical site 11 (9) 1 (3) NS 
Diagnostic workup    
Blood culture (sets): median number (IQR)  6 (4-9) 3.5 (2-7.5) <0.01 
Follow-up blood culture 84 (71) 14 (50) 0.04 
Positive at 48-72h 33/84 (39) 4/14 (29) NS 
Time to clearance: median days (IQR) 4 (2-6) 3 (2-4) NS 
Echocardiography    
Any 73 (59) 8 (26) < 0.01 
Transoesophageal 19 (17) 1 (3) 0.08 
Deep-seated sites of infection (≥ 1 possible)    
Any 53 (43) 5 (16) <0.01 
Cardiovascular 35 (28) 3 (9) 0.03 
Endocarditis 13 (11) 0 0.07 
Vascular prosthesis infection 13 (10) 1 (3) NS 
Septic thrombophlebitis 10 (8) 2 (6) NS 
Osteoarticular 24 (19) 1 (3) 0.03 
Osteomyelitis 9 (7)
*
 0 NS 
Septic arthritis 8 (6) 0 NS 
Sternitis 7 (6) 1 (3) NS 
Deep systemic emboli 6 (5)
**
 0 NS 
Deep-tissue abscess 6 (5)
†
 1 (3)
†
 NS 
Data are numbers. (%) unless indicated otherwise. IQR: interquartile range. ICU: intensive care unit. NS: not 392 
significant.  393 
*
 including 5 vertebral (3 of which associated with epidural abscess) and 3 foot osteomyelitis. 394 
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**
 including 2 lung, 3 retinal, 2 cerebral and 2 splenic emboli. 395 
†
 including 3 epidural, 2 retrosternal, 1 liver, 1 psoas abscesses. 396 
  397 
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Table 3. Management and outcome of MRSA bacteremia episodes with or without 398 
infectious diseases (ID) consultation. 399 
Characteristics 
ID consultation 
n=124 
No ID consultation 
n=32 
p-value 
Length of hospital stay: median days (IQR)    
From bacteremia onset to hospital discharge 27.5 (37-7) 22 (7-35) 0.02 
Total length of stay 56 (26-88) 33 (14-58) 0.01 
Antimicrobial therapy    
Empirical treatment (any) 85 (68) 20 (65) NS 
Targeted treatment (any) 124/124 (100) 32 (100) NS 
Appropriate treatment:    
Empirical 42/85 (49) 6/20 (30) NS 
Targeted 124/124 (100) 32 (100) NS 
Time to treatment
*
: median days (IQR) 1 (0-2) 1 (1-2) 0.08 
Duration of antimicrobial therapy:    
median days (IQR) 17 (13-30) 12 (3-14) < 0.01 
> 14 days 86 (71) 12 (39) <0.01 
> 28 days 37 (31) 3 (10) 0.02 
Vancomycin level measurement
**
 110/111 (99) 21/28 (77) <0.01 
Vancomycin trough level
†
: median (IQR) 13.7 (10.5-16.7) 13.1 (8.6-15.5) NS 
First measurement 11.65 (8.1-15.4) 10.3 (7.1-13.5) NS 
Measurement after dosage adaptation 14.9 (10.5-21.1) 14.1 (7.8-20) NS 
Eradication of removable infectious foci
‡
    
Any 70/84 (83) 8/14 (57) 0.03 
Peripheral catheter removal 5/5 (100) 2/2 (100) NS 
Central venous catheter removal  42/44 (95) 5/6 (83) NS 
Surgical debridement/drainage 25/41 (61%) 2/7 (28%) NS 
Outcome    
7-day mortality 6 (5) 7 (22) <0.01 
30-day mortality
§
 23/114 (20) 12/30 (40) 0.03 
In-hospital mortality 36 (29) 17 (53) 0.01 
 400 
Data are numbers (%) unless indicated otherwise. IQR: interquartile range. IQR: interquartile range. NS: not 401 
significant.  402 
*
 time elapsed from the day of first positive blood culture to start of appropriate therapy. 403 
**
 includes patient receiving vancomycin for at least 48h. 404 
†
 in mg/l. 405 
‡
 percentages refer only to episodes with a removable primary or deep-seated focus of infection. Two peripheral 406 
catheters had already been removed before MRSA bacteremia was diagnosed and were therefore not counted. 407 
§
 evaluable number of patients for that parameter. 408 
 409 
  410 
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Figure 1. Annual incidence of MRSA bacteremia episodes with or without infectious 411 
diseases (ID) consultation according to institutional policy. 412 
 413 
Figure 2. Kaplan-Meier survival curves. 414 
 415 
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Figure 3. Univariate and multivariate analyses of predictors of 7-day and 30-day mortality. 416 
Each dot and horizontal bar indicates odds ratio and 95% confidence interval. 417 
 418 
